742 related articles for article (PubMed ID: 12069915)
1. Voriconazole -- better chances for patients with invasive mycoses.
Ghannoum MA; Kuhn DM
Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections.
Cecil JA; Wenzel RP
Expert Rev Hematol; 2009 Jun; 2(3):237-54. PubMed ID: 21082966
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain].
Díaz Pedroche C; Cisneros JM; Lumbreras C; Aguado JM;
Rev Esp Quimioter; 2005 Jun; 18(2):149-58. PubMed ID: 16130037
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine.
Krishnan-Natesan S; Chandrasekar PH; Manavathu EK; Revankar SG
Diagn Microbiol Infect Dis; 2008 Dec; 62(4):443-6. PubMed ID: 18842377
[TBL] [Abstract][Full Text] [Related]
6. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
7. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
8. Antifungal activity of the new azole UK-109, 496 (voriconazole).
Kappe R
Mycoses; 1999; 42 Suppl 2():83-6. PubMed ID: 10865910
[TBL] [Abstract][Full Text] [Related]
9. [Voriconazole: a new weapon against invasive fungal infections].
Aoun M
Rev Med Brux; 2004 Jun; 25(3):166-71. PubMed ID: 15291449
[TBL] [Abstract][Full Text] [Related]
10. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole: therapeutic review of a new azole antifungal.
Herbrecht R
Expert Rev Anti Infect Ther; 2004 Aug; 2(4):485-97. PubMed ID: 15482215
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole : a review of its use in the management of invasive fungal infections.
Scott LJ; Simpson D
Drugs; 2007; 67(2):269-98. PubMed ID: 17284090
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
16. Changing strategies for the management of invasive fungal infections.
Rapp RP
Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole: a new triazole antifungal agent.
Johnson LB; Kauffman CA
Clin Infect Dis; 2003 Mar; 36(5):630-7. PubMed ID: 12594645
[TBL] [Abstract][Full Text] [Related]
18. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens.
Marangon FB; Miller D; Giaconi JA; Alfonso EC
Am J Ophthalmol; 2004 May; 137(5):820-5. PubMed ID: 15126145
[TBL] [Abstract][Full Text] [Related]
19. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model.
Takemoto K; Yamamoto Y; Ueda Y; Kanazawa K; Yoshida K; Niki Y
Chemotherapy; 2009; 55(2):105-13. PubMed ID: 19151551
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics of voriconazole in the management of invasive fungal infections.
Al-Badriyeh D; Heng SC; Neoh CF; Slavin M; Stewart K; Kong DC
Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):623-36. PubMed ID: 21155694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
